Sobi Q4 2025 Report
Revenue increased 16% at CER to SEK 7,821 million. Haematology sales grew 25% (CER) to SEK 5,143 million, driven by Altuvoct (SEK 1,023 million) and Doptelet (SEK 1,508 million), while Vonjo sales decreased. Immunology revenue reached SEK 2,337 million.




